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Other names: LuCa-2; LUCA2 
Location: 3p21.3 
Local order: Telomeric to TUSC2 and centromeric to 
HAYL1. 
Note: HYAL2 was identified in an EST database 
search of PH-20 hyaluronidase related sequences. 
HYAL2 appears to be an inactive hyaluronidase. 
Characterization of HYAL2 mostly focuses on its role 
as the cell entry receptor of Jaagsiekte sheep retrovirus 
(JSRV), and the putative function as a tumor 




The HYAL2 gene contains 4 exons, spanning 4.99 kb. 
Transcription 
The gene encodes two alternatively spliced transcripts 
(NM_033158 and NM_003773) which differ only in 
the 5' UTR. Distinct noncoding exon 1 was found in 
these two transcripts. Both variants encode the same 
protein. The ORF size is 1422 bp. 
Pseudogene 
No known pseudogenes. 
 
Two alternatively spliced variants (NM_033158.2 and NM_003773.2) of HYAL2 are shown. Both of them contain four exons. Black 
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Protein 
 
The HYAL2 protein contains a N-terminal signal peptide (1-20) and a epidermal growth factor (EGF)-like domain (365-469). 
Description 
The 473 amino-acid peptide encodes the HYAL2 
protein with a predicted molecular weight of 53.9 KDa. 
The protein is comprised of a N-terminal signal peptide 
(amino acids 1-20) and a epidermal growth factor 
(EGF)-like domain at amino acids 365-469 (by 
SMART prediction). 
Expression 
High level of HYAL2 expression was detected in most 
tissues, including liver, kidney, lung and heart. 
Expression was low or absent in brain. 
Localisation 
Originally shown to be lysosomal but subsequently 
proved to be a glycosylphosphatidylinositol (GPI)-
anchored cell surface protein. 
Function 
Hyaluronidases degrade hyaluronan, one of the major 
glycosaminoglycans of the extracellular matrix (ECM). 
The level of hyaluronan is regulated by a balance 
between hyaluronan synthase and HYAL enzyme 
activities. Hyaluronan is suggested to be involved in 
embryonic development, cell proliferation, migration 
and wound healing. Although originally supposed to be 
active at pH 4.0, HYAL2 actually displayed minimal to 
undetectable hyaluronidase activity in subsequent 
studies. The hyaluronidase activity of HYAL2 remains 
controversial. 
Homology 
HYAL2 belongs to a family of 
hyaluronoglucosaminidases. Other members include 
HYAL1, HYAL3, HYAL4 and Spam1. 
Mutations 







Possible in lung cancer and breast 
cancer 
Note: HYAL2 is located within a 120-kb minimal 
deletion region at 3p21.3 a chromosomal segment 
known to harbor multiple candidate tumor suppressor 
genes in breast and lung cancers. Nevertheless, HYAL2 
does not possess tumor suppressor function, as evident 
by in vitro and in vivo studies in lung cancer models. 
HYAL2 serves as the cellular receptor that mediates 
entry of the Jaagsiekte sheep retrovirus (JSRV), and its 
receptor function is independent on its catalytic 
activity. The JSRV envelope (Env) protein is believed 
to be the active oncogene. The viral Env transforms 
epithelial cells through activation of RON receptor 
tyrosine kinase, also called macrophage stimulating-1 
receptor (MST1R), and followed by activating 
PI3K/Akt signaling cascade and MAPK signaling 
cascade. HYAL2 physically interacts and negatively 
regulates RON. 
JSRV infects the epithelial cells of the lower airway of 
sheep and goats, resulting in ovine pulmonary 
adenocarinoma, sharing features with human 
bronchioloalveolar carcinoma. Danilkovitch-Miagkova 
et al. (2003) demonstrated activated RON in a subset of 
human bronchioloalveolar carcinoma tumors, 
suggesting RON involvement in this type of human 
lung cancer. 
Disease 
Lung cancer; bronchioloalveolar carcinoma; non-
Hodgkin lymphoma; breast cancer. 
Prognosis 
Increased level of HYAL2 deletions in sputum of Stage 
I non-small-cell lung cancer patients was associated 
with pack-years of smoking, but independent on 
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size and location. HYAL2 mRNA expression was 
inversely correlated with lymphoma aggressiveness. 
Oncogenesis 
HYAL2 mRNA expression was lost in lung cancer cell 
lines. However, expression of HYAL2 was retained in 
esophageal squamous carcinoma and nasopharyngeal 
carcinoma cell lines. Highly invasive breast cancer cell 
lines preferentially express HYAL2. 
Systemic administration of protamine-complexed 
vectors expressing HYAL2 inhibited lung metastatic 
foci in nu/nu mice. Intratumoral injection of same 
construct failed to suppress primary tumor growth or 
induce apoptosis, suggesting HYAL2 may function at 
the level of metastasis. 
References 
Lepperdinger G, Strobl B, Kreil G. HYAL2, a human gene 
expressed in many cells, encodes a lysosomal hyaluronidase 
with a novel type of specificity. J Biol Chem 
1998;273(35):22466-22470. 
Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, 
Duh FM, Gazdar AF, Lerman MI, Minna JD. Cloning of a 
breast cancer homozygous deletion junction narrows the 
region of search for a 3p21.3 tumor suppressor gene. 
Oncogene 1998;16(24):3151-3157. 
Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, 
Lerman MI, Miller AD. Candidate tumor suppressor HYAL2 is a 
glycosylphosphatidylinositol (GPI)-anchored cell-surface 
receptor for jaagsiekte sheep retrovirus, the envelope protein 
of which mediates oncogenic transformation. Proc Natl Acad 
Sci USA 2001;98(8):4443-4448. 
Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, 
Xu K, Yen N, Atkinson EN, Fang B, Lerman MI, Roth JA, 
Minna JD. Expression of several genes in the human 
chromosome 3p21.3 homozygous deletion region by an 
adenovirus vector results in tumor suppressor activities in vitro 
and in vivo. Cancer Res 2002;62(9):2715-2720. 
Danilkovitch-Miagkova A, Duh FM, Kuzmin I, Angeloni D, Liu 
SL, Miller AD, Lerman MI. Hyaluronidase 2 negatively 
regulates RON receptor tyrosine kinase and mediates 
transformation of epithelial cells by jaagsiekte sheep retrovirus. 
Proc Natl Acad Sci USA 2003;100(8):4580-4585. 
Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, 
Dammann R, Huang DP. RASSF1A is a target tumor 
suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J 
Cancer 2004;109(6):839-847. 
Bertrand P, Courel MN, Maingonnat C, Jardin F, Tilly H, 
Bastard C. Expression of HYAL2 mRNA, hyaluronan and 
hyaluronidase in B-cell non-Hodgkin lymphoma: relationship 
with tumor aggressiveness. Int J Cancer 2005;113(2):207-212. 
Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The over-
expression of HAS2, Hyal-2 and CD44 is implicated in the 
invasiveness of breast cancer. Exp Cell Res 2005;310(1):205-
217. 
Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, Fang 
HB, Katz RL, Stass SA, Jiang F. Genetic deletions in sputum 
as diagnostic markers for early detection of stage I non-small 
cell lung cancer. Clin Cancer Res 2007;13:482-487. 
Vigdorovich V, Miller AD, Strong RK. Ability of hyaluronidase 2 
to degrade extracellular hyaluronan is not required for its 
function as a receptor for jaagsiekte sheep retrovirus. J Virol 
2007;81(7):3124-3129. 
This article should be referenced as such: 
Chow LSN, Lo KW. HYAL2 (hyaluronoglucosaminidase 2). 
Atlas Genet Cytogenet Oncol Haematol.2008;12(4):279-281.  
 
